Clinical Study of High Concentration Ganciclovir Eye Drops in the Treatment of Cytomegalovirus Retinitis
Key facts
- Where
- Tianjin, ChinaSee the site
- Phase
- Early phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 2 and 80 years old?
Source: NCT05911503, who can take part
Where in China
- Tianjin Medical University Eye HospitalTianjin, ChinaContact: xiaomin ZhangTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Tianjin Medical University
- Trial code
- NCT05911503
- Record updated
- 23 June 2023
- Original description
Clinical study of high concentration ganciclovir eye drops in the treatment of cytomegalovirus retinitisRead full original descriptionShow less
A Clinical Study of High Concentration(2%) Ganciclovir Eye Drops in the Treatment of Cytomegalovirus Retinitis
Clinical study of high concentration ganciclovir eye drops in the treatment of cytomegalovirus retinitis
Inclusion: Patients voluntarily participate in studies and sign informed consent forms; Ages 2-80 years (with cut-off values) male and female; One of the following is true （1）In patients with cytomegalovirus retinitis after hematopoietic stem cell transplantation/cord blood transplantation, the white blood cell count is less than 4× 10\^9/L, and the platelet count ranges are 25× 10\^9/L≤ PLT<100×10\^9/L，Intravitreal injection carries a greater risk of infection and bleeding, and is unable to administer systemic medication due to the bone marrow suppression of antiviral drugs, or systemic medication for severe CMV retinitis cannot be well controlled; （2）In patients with CMVR with AIDS, the CD4+ T cell count is less than 100/μl, there is a great risk of infection with intravitreal injection, and the systemic medication of severe CMV retinitis cannot be well controlled.
Exclusion: Eye condition; The presence of refractive interstitial opacification affects fundus observation; Intravitreal ganciclovir or sodium phosformate injections were performed within 1 week prior to baseline; Other diseases that can affect visual function such as syphilis-related eye diseases, acute retinal necrosis, congenital glaucoma, congenital corneal lesions, congenital macular degeneration, etc; General condition; Severe neutropenia (<0.5×10\^9) or severe thrombocytopenia (< 25× 10\^9/L); Other investigators judged patients who were not suitable for enrollment.